Target intelligence / Profile preview

Pneumococcal surface adhesin A (PsaA) (PsaA)

Target
PsaA
Molecular classification
Lipoprotein, Metal-binding protein, Adhesin, ABC transporter substrate-binding protein
01

Overview

Pneumococcal surface adhesin A (PsaA) is a 37-kDa metal-binding lipoprotein and a member of the LraI protein family, essential for the virulence of Streptococcus pneumoniae (UniProt: P0A4G2). It functions as the substrate-binding protein for the PsaABC ATP-binding cassette (ABC) transporter, which is the primary system for high-affinity manganese (Mn2+) uptake in the pathogen (McAllister et al., 2004, J. Biol. Chem.). Manganese is a vital cofactor for the pneumococcal superoxide dismutase (SodA), which allows the bacteria to neutralize reactive oxygen species and survive the host's oxidative burst (Couñago et al., 2014, Structure). Additionally, PsaA acts as an adhesin, mediating the attachment of the bacteria to E-cadherin on human nasopharyngeal epithelial cells, a critical step for colonization (Rajam et al., 2008, Crit. Rev. Microbiol.). Due to its high conservation across nearly all known pneumococcal serotypes, PsaA is a leading candidate for next-generation, serotype-independent protein vaccines (Luo et al., 2012, Vaccine). Therapeutic strategies focusing on PsaA typically involve the induction of neutralizing antibodies that block bacterial colonization and impair the pathogen's ability to survive oxidative stress.

Other names
Manganese-binding lipoprotein PsaA37 kDa surface antigenLraI family proteinPneumococcal surface antigen A
02

Mechanism of action

Induction of antibodies that inhibit bacterial adhesion to host cells and disrupt manganese acquisition, leading to reduced bacterial fitness and clearance.

03

Biological functions

Manganese ion transportCell adhesionResponse to oxidative stressBacterial colonization
04

Disease associations

InfectionPneumoniaMeningitisBacteremiaOtitis media
05

Safety considerations

Potential for immune-mediated adverse reactionsTheoretical risk of affecting commensal streptococciVaccine-induced serotype replacement (though less likely with conserved protein targets)
06

Interacting drugs

Pneumococcal protein vaccine (experimental)

1 more in the full profile.

07

Biomarkers

Anti-PsaA IgG antibody titerManganese uptake inhibition (experimental)

Beyond the preview

Go deeper on Pneumococcal surface adhesin A (PsaA) (PsaA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pneumococcal surface adhesin A (PsaA) (PsaA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call